Clinical research & EBM · Reference
What are the phases of a clinical trial?
Clinical trial phases are the staged sequence — Phase 0 through Phase 4 — through which a new drug is evaluated. Each phase asks a narrower question, enrols more participants, and gates progression to the next, concentrating early risk in small, closely monitored studies.
Phases 0 and 1: first studies in people
Phase 0 (exploratory) studies use very small, sub-therapeutic exposures in a handful of volunteers to gather early data on how the body handles a candidate compound, without aiming to produce a clinical effect. Phase 1 studies are the first to test the intervention more substantially in people, usually a small group of healthy volunteers, with the primary purpose of assessing safety, tolerability and how the body processes the agent. These early phases are about characterising basic human pharmacology rather than demonstrating benefit, and they are closely monitored because the most uncertainty about human effects exists at this stage.
Phases 2 and 3: efficacy and comparison
Phase 2 studies enrol a larger group of participants who have the condition of interest and look for early evidence of efficacy while continuing to monitor safety. They help refine which approach is worth testing at scale. Phase 3 studies are large, often multi-centre comparative trials, frequently randomized controlled trials, that compare the intervention against a placebo or standard care to confirm effectiveness and detect less common adverse effects. Phase 3 typically provides the pivotal evidence that regulators such as the FDA assess for approval.
Phase 4: post-marketing surveillance
Phase 4 studies take place after a product has been approved and is in routine use. Because pre-approval trials are limited in size and duration, Phase 4 surveillance — including pharmacovigilance — monitors long-term safety and effectiveness across much larger and more diverse populations. It can detect rare adverse effects, interactions and outcomes in groups under-represented in earlier phases. Together the phases form a methodological pipeline that escalates the scale of evaluation only as evidence accumulates.
Key facts
At a glance
- Phase 0: Exploratory, sub-therapeutic, very few volunteers
- Phase 1: First substantial human study; safety and tolerability
- Phase 2: Early efficacy in people with the condition
- Phase 3: Large comparative trials; pivotal evidence for approval
- Phase 4: Post-marketing surveillance and pharmacovigilance
Common questions
FAQ
What is the difference between Phase 1 and Phase 3 trials?+
Phase 1 trials are small first-in-human studies focused on safety and how the body handles the agent, often in healthy volunteers. Phase 3 trials are large comparative studies in patients that confirm effectiveness and detect less common adverse effects, and they usually provide the pivotal evidence for regulatory approval.
What happens in a Phase 4 trial?+
Phase 4 studies occur after approval, when the product is in routine use. They monitor long-term safety and effectiveness in much larger and more varied populations, allowing rare adverse effects and interactions to be detected that smaller earlier trials could not.
Why are clinical trials done in phases?+
Staging concentrates the greatest uncertainty in small, closely monitored studies and reserves large, expensive trials for interventions that have already shown promise. Each phase gates progression to the next, which is a safeguard for participants and an efficient use of resources.
Going deeper
Related on CASRAI
Sources
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
